Reported Tuberculosis in the United States, 2022

Return to Main Menu

Table 11. Tuberculosis Cases and Percentages by Drug Resistance: United States, 1993–2022

 

Tuberculosis Cases and Percentages by Drug Resistance: United States, 1993–2022
Year Total cases1 Isoniazid (INH)-resistant2 Multidrug-resistant (MDR)3 Pre-extensively drug-resistant (Pre-XDR)4 Extensively drug-resistant (XDR)5
No. (%) No. (%) No. (%) No. (%)
2022 6,251 528 (8.4) 90 (1.4) 16 (0.3) 5 (0.1)
2021 6,075 539 (8.9) 78 (1.3) 6 (0.1) 2 (0.0)
2020 5,578 457 (8.2) 56 (1.0) 7 (0.1) 1 (0.0)
2019 6,915 662 (9.6) 93 (1.3) 16 (0.2) 3 (0.0)
2018 6,885 642 (9.3) 104 (1.5) 15 (0.2) 1 (0.0)
2017 6,891 633 (9.2) 129 (1.9) 22 (0.3) 4 (0.1)
2016 7,043 651 (9.2) 97 (1.4) 17 (0.2) 1 (0.0)
2015 7,305 685 (9.4) 88 (1.2) 6 (0.1) 1 (0.0)
2014 7,107 688 (9.7) 94 (1.3) 13 (0.2) 2 (0.0)
2013 7,178 672 (9.4) 96 (1.3) 14 (0.2) 5 (0.1)
2012 7,451 685 (9.2) 88 (1.2) 11 (0.1) 2 (0.0)
2011 7,910 752 (9.5) 127 (1.6) 16 (0.2) 5 (0.1)
2010 8,226 692 (8.4) 106 (1.3) 10 (0.1) 2 (0.0)
2009 8,657 762 (8.8) 115 (1.3) 18 (0.2) 0 (0.0)
2008 9,875 838 (8.5) 107 (1.1) 14 (0.1) 6 (0.1)
2007 10,246 799 (7.8) 124 (1.2) 10 (0.1) 2 (0.0)
2006 10,480 845 (8.1) 124 (1.2) 12 (0.1) 4 (0.0)
2005 10,647 842 (7.9) 125 (1.2) 21 (0.2) 3 (0.0)
2004 11,100 872 (7.9) 128 (1.2) 21 (0.2) 4 (0.0)
2003 11,385 904 (7.9) 119 (1.0) 22 (0.2) 0 (0.0)
2002 11,554 915 (7.9) 158 (1.4) 23 (0.2) 6 (0.1)
2001 12,294 897 (7.3) 151 (1.2) 25 (0.2) 4 (0.0)
2000 12,558 981 (7.8) 146 (1.2) 20 (0.2) 1 (0.0)
1999 13,484 1,000 (7.4) 157 (1.2) 22 (0.2) 6 (0.0)
1998 14,275 1,121 (7.9) 155 (1.1) 26 (0.2) 1 (0.0)
1997 15,270 1,195 (7.8) 201 (1.3) 32 (0.2) 2 (0.0)
1996 16,329 1,284 (7.9) 250 (1.5) 42 (0.3) 3 (0.0)
1995 17,094 1,352 (7.9) 327 (1.9) 57 (0.3) 1 (0.0)
1994 17,623 1,543 (8.8) 431 (2.4) 78 (0.4) 6 (0.0)
1993 17,705 1,534 (8.7) 484 (2.7) 77 (0.4) 10 (0.1)

1Persons with isolates tested with at least isoniazid and rifampin.
2Resistance to at least isoniazid.
3Resistance to at least isoniazid and rifampin.
4MDR TB with additional resistance to either a fluoroquinolone or second-line injectable.
5MDR TB with additional resistance to fluoroquinolones and resistance to a second-line injectable, bedaquiline, or linezolid.

Note:
Data for all years updated through July 8, 2023.